ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Summit Therapeutics (SMMT) pipeline and stated timing

Name in SEC filings: Summit Therapeutics Inc.

Pipeline at a glance

ProgramEventStageStated timingFiling
ivonescimabEvent-based analysisStage not statedin the second half of 202610-Q ·
ivonescimabEvent-based analysisStage not statedin the first half of 202710-Q ·
ivonescimabEvent-based analysisStage not statedfor the first half of 202710-Q ·
ivonescimabSite activationStage not statedby the fourth quarter of 20268-K ·

Source: ORION, orionbiotechai.com/company/SMMT, data as of Oct 16, 2026
https://www.orionbiotechai.com/company/SMMT

Nearest upcoming stated timing: ivonescimab · Event-based analysis · in the second half of 2026

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

ivonescimab

Matched

Event-based analysisin the second half of 2026

Stage: Not stated

Public float: Unknown (no public float found in SEC filings).

The number of PFS events needed in the squamous cohort for the primary analysis is expected to be reached in the second half of 2026, and a planned early interim analysis for OS is expected to take place in conjunction with the primary PFS analysis.

SEC timing context:

HARMONi-3

10-Q · Filed · Last checked

Source details

Accession 0001599298-26-000068

SEC accepted the filing

Alert me · Calendar: same stage and window-end month (2026-12)

ivonescimab

Matched

Event-based analysisin the first half of 2027

Stage: Not stated

Public float: Unknown (no public float found in SEC filings).

For this cohort, the number of events needed to conduct the PFS analysis is expected to be reached in the first half of 2027.

SEC timing context:

Enrollment in the non-squamous cohort of the global HARMONi-3 study was completed in the second quarter of 2026.

10-Q · Filed · Last checked

Source details

Accession 0001599298-26-000068

SEC accepted the filing

Alert me · Calendar: same stage and window-end month (2027-06)

ivonescimab

Matched

Event-based analysisfor the first half of 2027

Stage: Not stated

Public float: Unknown (no public float found in SEC filings).

An interim analysis for overall survival independent of PFS is planned for the first half of 2027.

SEC timing context:

HARMONi-3

10-Q · Filed · Last checked

Source details

Accession 0001599298-26-000068

SEC accepted the filing

Alert me · Calendar: same stage and window-end month (2027-06)

ivonescimab

Matched

Site activationby the fourth quarter of 2026

Stage: Not stated

Public float: Unknown (no public float found in SEC filings).

Summit announced initiation of HARMONi-GU1, a Phase II/III study in urothelial carcinoma (bladder cancer) with global clinical trial site activations planned to begin by the fourth quarter of 2026.

8-K · Filed · Last checked

Source details

Accession 0001193125-26-405776

SEC accepted the filing

Alert me · Calendar: same stage

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

Program / eventStated period and SEC wordingDisclosure in stated period
ivonescimabSite activationby the fourth quarter of 2026
“Summit announced initiation of HARMONi-GU1, a Phase II/III study in urothelial carcinoma (bladder cancer) with global clinical trial site activations planned to begin by the fourth quarter of 2026.”

Filed · EX-99.1

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

ivonescimabEvent-based analysisin the first half of 2027
“For this cohort, the number of events needed to conduct the PFS analysis is expected to be reached in the first half of 2027.”

Filed · 10-Q

Period not started

The stated period has not started yet, so there is nothing to compare.

ivonescimabEvent-based analysisfor the first half of 2027
“An interim analysis for overall survival independent of PFS is planned for the first half of 2027.”

Filed · 10-Q

Period not started

The stated period has not started yet, so there is nothing to compare.

ivonescimabEvent-based analysisin the second half of 2026
“The number of PFS events needed in the squamous cohort for the primary analysis is expected to be reached in the second half of 2026, and a planned early interim analysis for OS is expected to take place in conjunction with the primary PFS analysis.”

Filed · 10-Q

Still within period

As of Oct 19, 2026

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch SMMT

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for SMMT. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See SMMT in the calendar · Review labels and methodology